a clinical study of zilovertamab vedotin (mk-2140) plus rituximab plus cyclophosphamide, doxorubicin, and prednisone (r-chp) versus polatuzumab vedotin plus r-chp in people with diffuse large b-cell lymphoma (dlbcl) (mk-2140-011/waveline-011)

Conditions: Lymphoma, Large B-Cell, Diffuse

Summary: researchers are looking for ways to treat germinal center b-cell-like diffuse large b-cell lymphoma (gcb dlbcl). dlbcl is a fast-growing blood cancer that affects b-cells. gcb is a type of dlbcl that affects young b-cells that are still maturing. the goal of this study is to learn if more people who receive zilovertamab vedotin (mk-2140) and r-chp have the cancer respond (go away) than those who receive polatuzumab vedotin and r-chp.


Eligibility criteria:
inclusion criteria: the main inclusion criteria include but are not limited to the following: * has histologically confirmed diagnosis of germinal center b-cell (gcb) subtype of diffuse large b-cell lymphoma (dlbcl), by prior biopsy, according to the world health organization (who) classification of neoplasms of the hematopoietic and lymphoid tissues. * has positron emission tomography (pet) positive disease at screening, defined as 4 to 5 on the lugano 5-point scale. * has received no prior treatment for their dlbcl. * human immunodeficiency virus (hiv) infected participants must have well controlled hiv on antiretroviral therapy (art). * participants who are hepatitis b surface antigen (hbsag) positive are eligible if they have received hepatitis b virus (hbv) antiviral therapy and have undetectable hbv viral load prior to randomization. * participants with history of hepatitis c virus (hcv) infection are eligible if hcv viral load is undetectable at screening. exclusion criteria: the main exclusion criteria include but are not limited to the following: * has a history of transformation of indolent disease to dlbcl. * has received a diagnosis of primary mediastinal b-cell lymphoma (pmbcl) or grey zone lymphoma. * has ann arbor stage i dlbcl. * has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\<6 months prior to enrollment), unstable angina, congestive heart failure (new york heart association classification class ≥ii), or serious cardiac arrhythmia requiring medication. * has clinically significant pericardial or pleural effusion. * has ongoing grade \>1 peripheral neuropathy. * has a demyelinating form of charcot-marie-tooth disease. * hiv-infected participants with a history of kaposi's sarcoma and/or multicentric castleman's disease. * has ongoing corticosteroid therapy. * known additional malignancy that is progressing or has required active treatment within the past 2 years. * known active central nervous system (cns) lymphoma. * has active autoimmune disease that has required systemic treatment in the past 2 years. * has active infection requiring systemic therapy. * has active hbv (defined as hbsag positive and detectable hbv deoxyribonucleic acid (dna)) and hcv (defined as anti-hcv antibody positive and detectable hcv ribonucleic acid (rna)) infection. * has history of stem cell/solid organ transplant.